Guselkumab
- Generic Name
- Guselkumab
- Brand Names
- Tremfya
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1350289-85-8
- Unique Ingredient Identifier
- 089658A12D
- Background
Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstrated improved skin clearance and symptoma...
- Indication
Indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- Associated Conditions
- Severe Plaque psoriasis, Moderate Plaque psoriasis
- Associated Therapies
- -
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
- Conditions
- Interventions
- Drug: Squaric Acid Dibutyl EsterOther: Known patch test allergensDevice: MicroneedleDrug: DupilumabDevice: Suction blisteringDrug: AdalimumabProcedure: Skin punch biopsyDrug: UstekinumabDrug: GuselkumabDrug: CanakinumabDrug: SarilumabDrug: Triamcinolone AcetonideDrug: Betamethasone ValerateDrug: Fluticasone Propionate
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- John Harris
- Target Recruit Count
- 45
- Registration Number
- NCT05535738
- Locations
- 🇺🇸
University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 280
- Registration Number
- NCT05347095
- Locations
- 🇯🇵
Osaka University Hospital, Suita, Japan
🇯🇵Kyorin University Hospital, Tokyo, Japan
🇯🇵Ieda Hospital, Toyota, Japan
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 213
- Registration Number
- NCT05272150
- Locations
- 🇺🇸
Austin Institute for Clinical Research, Pflugerville, Texas, United States
🇺🇸Florida Academic Dermatology Centers, Coral Gables, Florida, United States
🇺🇸Hollywood Dermatology and Cosmetic Surgery, Hollywood, Florida, United States
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 703
- Registration Number
- NCT05242471
- Locations
- 🇺🇸
Moore Clinical Trials, LLC, Little Rock, Arkansas, United States
🇺🇸Om Research LLC, Apple Valley, California, United States
🇺🇸Valley Gastroenterology Medical Group, Arcadia, California, United States
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 577
- Registration Number
- NCT05242484
- Locations
- 🇯🇵
University Hospital Kyoto Prefectural University of Medicine, Kyoto, Japan
🇯🇵Kyoto University Hospital, Kyoto, Japan
🇯🇵Gunma University Hospital, Maebashi, Japan
Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT05125679
- Locations
- 🇬🇷
Attikon Hospital, Athens, Greece
🇮🇹Ospedale San Giovanni di Dio, Cagliari, Italy
🇩🇪Universitatsklinikum Frankfurt, Frankfurt, Germany
A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 11
- Registration Number
- NCT05083078
- Locations
- 🇦🇹
Medical University Graz, Graz, Austria
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT05083182
- Locations
- 🇩🇰
Aarhus Universitetshospital, Arhus, Denmark
🇩🇰Odense Universitets Hospital, Odense, Denmark
🇫🇷CHU de Caen, Caen, France
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2021-10-08
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 91
- Registration Number
- NCT05071664
- Locations
- 🇺🇸
Great Lakes Center of Rheumatology, Lansing, Michigan, United States
🇺🇸Clinvest, Springfield, Missouri, United States
🇺🇸Jacobi Medical Center, Bronx, New York, United States
A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 1314
- Registration Number
- NCT05049798
- Locations
- 🇩🇪
Universitatsklinikum Dusseldorf, Dusseldorf, Germany
🇦🇷Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
🇦🇷Hospital J. M. Ramos Mejía, Buenos Aires, Argentina
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.